| ABH antigenicity of in situ carcinoma of the urinary bladder during intracavity treatment with doxorubicin hydrochloride. | |
| | |
MedLine Citation:
|
PMID: 7257030 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ten patients with carcinoma in situ of the urinary bladder were treated topically with doxorubicin hydrochloride. Blood group antigens were evaluated by the specific red cell adherence tests. Carcinoma in situ was associated with the loss of antigenicity, the reappearance of which could be demonstrated in patients with tumour remission. This occurred in spite of a persistent nuclear atypia. |
| | |
Authors:
|
G Jakse; F Hofstädter |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Urological research Volume: 9 ISSN: 0300-5623 ISO Abbreviation: Urol. Res. Publication Date: 1981 |
Date Detail:
|
Created Date: 1981-09-22 Completed Date: 1981-09-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0364311 Medline TA: Urol Res Country: GERMANY, WEST |
Other Details:
|
Languages: eng Pagination: 153-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
ABO Blood-Group System
/
immunology* Aged Carcinoma in Situ / drug therapy*, immunology, pathology Doxorubicin / therapeutic use* Female Humans Male Middle Aged Urinary Bladder Neoplasms / drug therapy*, immunology, pathology |
| Chemical | |
Reg. No./Substance:
|
0/ABO Blood-Group System; 23214-92-8/Doxorubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effects of low-dose heparin treatment on patients undergoing transvesical prostatectomy.
Next Document: Voiding disorders in young male adult.